Shanghai ZJ Bio-Tech CoSHSE:688317 -1.19%65 Net Current Asset Value is ¥13.06 as of Mar. 2026, which is 100% below its 10-year median of 1.51. GuruFocus rates SHSE:688317 with a GF Score™ of 65/100 and a GF Value™ of ¥9.90 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 567 Medical Devices & Instruments companies, Shanghai ZJ Bio-Tech Co ranks better than 93.65% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Shanghai ZJ Bio-Tech Co's net current asset value per share for the quarter that ended in Mar. 2026 was ¥13.06.
The historical rank and industry rank for Shanghai ZJ Bio-Tech Co's Net Current Asset Value or its related term are showing as below:
SHSE:688317'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.95 Med: 1.51 Max: 4.28
Current: 1.2
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Shanghai ZJ Bio-Tech Co was 4.28. The lowest was 0.95. And the median was 1.51.
SHSE:688317's Price-to-Net-Current-Asset-Value is ranked better than 93.65% of 567
companies
in the Medical Devices & Instruments industry
Industry Median: 5
vs SHSE:688317: 1.20
Shanghai ZJ Bio-Tech Co (SHSE:688317) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Shanghai ZJ Bio-Tech Co Net Current Asset Value Related Terms
Shanghai ZJ Bio-Tech Co Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Shanghai ZJ Bio-Tech Co's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai ZJ Bio-Tech Co Net Current Asset Value Chart
SHSE:688317 vs ABT, SYK, MDT: Net Current Asset Value Comparison
For the Medical Devices subindustry, Shanghai ZJ Bio-Tech Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai ZJ Bio-Tech Co Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai ZJ Bio-Tech Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Shanghai ZJ Bio-Tech Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ¥13.06 mean?
Shanghai ZJ Bio-Tech Co (SHSE:688317) has a Net Current Asset Value of ¥13.06 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. This is 765% above median its historical median of 1.51. Over the past decade, Shanghai ZJ Bio-Tech Co's Net Current Asset Value has ranged from 0.95 to 4.28. According to the industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #36 out of 567 companies in the Medical Devices & Instruments industry, placing it in the top 6.3%.
Is Shanghai ZJ Bio-Tech Co's Net Current Asset Value too high?
Shanghai ZJ Bio-Tech Co's current Net Current Asset Value of ¥13.06 is 765% above median its 10-year median of 1.51. Over the past 10 years, this metric has ranged from a low of 0.95 to a high of 4.28. Based on the distribution chart, Shanghai ZJ Bio-Tech Co ranks #36 out of 567 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai ZJ Bio-Tech Co has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai ZJ Bio-Tech Co's Net Current Asset Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #36 out of 567 companies for Net Current Asset Value. This places Shanghai ZJ Bio-Tech Co in the top 6% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 5.00. Historically, Shanghai ZJ Bio-Tech Co's own Net Current Asset Value has ranged from 0.95 to 4.28 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 5.00, based on 567 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai ZJ Bio-Tech Co's current Net Current Asset Value is ¥13.06, which is 765% above median its own 10-year median of 1.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai ZJ Bio-Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co (SHSE:688317) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥9.90, compared to a current price of ¥15.73 — trading 58.9% above its estimated fair value. The current Net Current Asset Value is ¥13.06, which is 765% above median its 10-year median of 1.51. Shanghai ZJ Bio-Tech Co's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Shanghai ZJ Bio-Tech Co (SHSE:688317), the current Net Current Asset Value is ¥13.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai ZJ Bio-Tech Co (SHSE:688317) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co stock appears to be overvalued.
The current stock price of ¥15.73 is trading 58.9% above its estimated GF Value™ of ¥9.90.
GuruFocus considers Shanghai ZJ Bio-Tech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688317:
Net Current Asset Value: ¥13.06 (765% above median its 10-year median of 1.51)
GF Value™: ¥9.90 vs. price of ¥15.73 (58.9% above fair value)
No single metric tells the full story. See the SHSE:688317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai ZJ Bio-Tech Co Ltd is engaged in research and development, production and sales of genetic diagnostic reagents and instruments and equipment. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture and other fields.
65GF Score
Get the complete analysis for SHSE:688317
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688317 has been successfully added to your 
